文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

胰头腺癌全胰切除与胰十二指肠切除术的围术期及肿瘤学结局:德国癌症登记组的倾向性评分匹配分析

Perioperative and oncologic outcomes after total pancreatectomy and pancreatoduodenectomy for pancreatic head adenocarcinoma-A propensity score-matched analysis from the German Cancer Registry Group.
PubMed 文献 · Surgery · 2025-03-17

基于德国癌症登记组数据,对2016年以来因胰头腺癌行根治性胰十二指肠切除术或全胰切除术的患者进行倾向性评分匹配,每组756例。结果显示胰十二指肠切除术的30天和90天死亡率显著更低,更多患者接受辅助化疗且间隔更短,长期总生存更优;全胰切除术围术期死亡率和长期生存均较差。

要点

  • 胰十二指肠切除术30天和90天死亡率显著低于全胰切除术。
  • 胰十二指肠切除术后更多患者接受辅助化疗且开始时间更早。
  • 全胰切除术后长期总生存更差,即使接受辅助化疗亦然。

核心结论

  • 胰头腺癌行全胰切除术较胰十二指肠切除术围术期死亡率和长期生存均更差。
  • 胰十二指肠切除术应作为胰头腺癌的标准术式,全胰切除术仅限选定患者。

研究设计与样本

  • 基于德国癌症登记组参与区域癌症登记处的匿名汇总数据。
  • 纳入2016年以来诊断为胰头腺癌并接受根治性胰十二指肠切除术或全胰切除术的患者。
  • 按年龄、性别和组织病理学进行倾向性评分匹配,每组756例。
  • 主要终点为术后30天和90天死亡率,次要终点包括辅助化疗、长期生存和复发模式。

临床怎么用

  • 胰头腺癌应优先选择胰十二指肠切除术作为标准术式。
  • 全胰切除术仅应在选定患者中施行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare perioperative morbidity and mortality in patients receiving pancreatoduodenectomy or total pancreatectomy for pancreatic head adenocarcinoma using German Cancer Registry data. METHODS: Anonymized pooled data were retrieved from regional cancer registries participating in the German Cancer Registry Group of the Association of German Tumor Centers. Included were patients diagnosed with pancreatic head adenocarcinoma since 2016, receiving curative intent pancreatoduodenectomy or total pancreatectomy. Patients were propensity-score matched according to age, sex, and histopathology. Primary endpoints were 30- and 90-day postoperative mortality. Secondary endpoints were administration of adjuvant chemotherapy, long-term survival, and patterns of cancer recurrence. The data were analyzed using R. RESULTS: In total, 756 patients per treatment group were matched for further analyses. R0-resection rate was comparable between pancreatoduodenectomy and total pancreatectomy (69.6 vs 73.4%, P = .154). The 30-day (9.5 vs 4.8%, P < .001) and 90-day postoperative mortality (18.0 vs 11.0%, P < .001) rates were significantly lower after pancreatoduodenectomy compared with total pancreatectomy. After pancreatoduodenectomy, more patients received adjuvant chemotherapy (43.6 vs 53.3%, P < .001) and time to adjuvant chemotherapy was shorter (60.1 vs 52.7 days, P = .002) compared with total pancreatectomy. Long-term overall survival was worse after total pancreatectomy (P < .001), also in patients receiving adjuvant chemotherapy (P = .019). The sites of recurrence were comparable between both groups (P = .274). CONCLUSION: The results of this study show greater perioperative morbidity and mortality after total pancreatectomy compared with pancreatoduodenectomy for pancreatic head malignancy. Also, long-term survival was worse after total pancreatectomy. These results emphasize the role of pancreatoduodenectomy as a standard surgical procedure for pancreatic head adenocarcinoma and suggest that total pancreatectomy should only be performed in selected patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Duhn J, von Fritsch L, Bolm L, et al. Perioperative and oncologic outcomes after total pancreatectomy and pancreatoduodenectomy for pancreatic head adenocarcinoma-A propensity score-matched analysis from the German Cancer Registry Group. Surgery. 2025. PMID: 40101369. doi:10.1016/j.surg.2025.109292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。